Advantages and safety of local treatment with MMC/Beriplast P for cancer tumors
Advantages and safety of local treatment with MMC/Beriplast P for cancer tumors
复制标题
MMC/Beriplast P 局部治疗癌症肿瘤的优点和安全性
DOI：
10.1007/s002800050519
复制
发表时间：
1996
影响因子：
3
通讯作者：
H. Tomoda
中科院分区：
文献类型：
--
作者：
H. Matsuoka;K. Yano;Y. Katsuta;M. Morita;S. Kounoe;Y. Seo;Takao Saito;H. Tomoda
To target the treatment of small points of cancer, Beriplast P, already used clinically as a physiological tissue adherent drug carrier, was mixed with the anticancer drug, mitomycin C (MMC). In this in vitro study, MMC did not release quickly from the clot of MMC/Beriplast P. The antitumor effect of this mixture was examined for its effect on cancer growth. In one series of experiments, tumor tissues were inoculated with MMC/100 μl Beriplast P and in another series, MMC/100 μl Beriplast P was injected into tumors at a weight of 300 mg. In the first series of experiments, tumor tissue treated with 0.3 mg MMC/100 μl Beriplast P was replaced with plasma cells and lymphocytes, and no viable cancer cells could be found. In the second series, MMC/100 μl Beriplast P delayed tumor growth, and the survival of Balb/c mice injected with 0.08 mg MMC/100 μl Beriplast P was significantly longer than that of mice injected with 0.08 mg MMC/100 μl saline solution (P=0.026). In addition, the abdominal aorta, vena cava, and intestine around the area of treatment with 1.6 mg MMC/100 μl Beriplast P were not damaged. These results indicate that the mixture of Beriplast P and MMC is more effective than MMC solution alone in the local treatment of residual cancer.
影响因子：
168.9
作者：
HAGIWARA, A;TAKAHASHI, T;SAKAKURA, C
通讯作者：
SAKAKURA, C